Articles
| Open Access | CONTINUITY OF ANTICOAGULANT TREATMENT IN PATIENTS WITH COVID-19
Suramisova Aygul Tursinbekovna,Roziboyeva Barno Abdinabievna , Ph.D. Senior teacher of International Kazakh-Turkish University named after Khoja Ahmed Yasavi; Kentau Central City Hospital, Head of the Department of Infectious Diseases, Senior Infectious Diseases Specialist,Republic of Kazakhstan. Kentau Central City Hospital. Doctor of infectious diseases of the first category.Abstract
anticoagulant therapy has gained importance during the COVID-19 pandemic due to changes in the blood coagulation system of patients, increasing the risk of thrombosis and embolism. This abstract provides a summary of the duration, indications, risks, and monitoring of anticoagulant therapy in patients with COVID-19. The disease COVID-19 causes changes in blood coagulation in many patients, which increases the risk of thrombotic events. Anticoagulants, such as low molecular weight heparins, play an important role in the prevention and treatment of thrombosis.
Keywords
COVID-19, thrombosis, embolism, blood coagulation system, preventive treatment, drug doses, risk of bleeding, medical professionals, duration of treatment, patient, prevention.
References
https://uz.m.wikipedia.org/w/index.php?title=COVID-19_pandemiyasi&wprov=rarw1
Sanitary rules, norms and hygiene regulations for the prevention of infections in medical organizations adapted to the treatment of COVID-19 infection. 2021
NEW PRINCIPLES OF ANTICOAGULANT THERAPY IN PATIENTS WITH COVID-19 Authors I. E. Irgashev
https://yuz.uz/uz/news/covid-19ni-davulashda-kandayi-dori-darmonas-kolaridad
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.